Earlier this year, Tokio Marine HCC – Stop Loss Group (TMHCC) released a much-needed product solution for gene therapy treatments that benefit our policyholders through a step down deductible. We want to thank you for the 400+ business partners that attended our webinar announcing the rollout of this product offering. If you missed it, you can view a recording of it here.

As a recap, TMHCC partnered with ETS to offer a solution for managing the high costs of cell and gene therapy treatments. Through implementation of the suggested Plan Document language provided by ETS, TMHCC stop loss policyholders will receive a 10% reduction in the specific deductible for the patient receiving gene therapy through an ETS program. The 10% step down deductible has a minimum of $15,000 and a maximum of $50,000, making the percentage more than 10% for groups with specific deductibles under $150,000. TMHCC will also cover the ETS access fee for utilizing their services.

Please refer to TMHCC's Best Practices in Cell & Gene Therapy for details on how the step down deductible can save your clients' money on gene therapy treatments.

Contact your regional marketing representative to learn more on how TMHCC’s partnership with ETS can positively impact your clients’ healthcare plans. 

TMHCC is a leading provider of medical stop loss coverage provided through brokers, consultants and third-party administrators. By listening to the demands of the market, we have developed exceptional products, unparalleled resources and value-added services that set us apart in the industry. Visit our website to learn more about our innovative stop loss, Taft-Hartley, captive and organ transplant solutions.